Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2 Colorectal Neoplasms 2 Hepatitis 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Chemical and Drug Induced Liver Injury 1 Breast Neoplasms 1 Barrett Esophagus 1

Interventions

Mycophenolic Acid 2 vedolizumab 1 Ursodeoxycholic Acid 1 Steroids 1 Sofosbuvir 1 Ribavirin 1 Prednisone 1 Photopheresis 1 Methylprednisolone Hemisuccinate 1 Methylprednisolone 1 Methoxsalen 1 Infliximab 1 Azathioprine 1 Adrenal Cortex Hormones 1 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hepatitis × Ursodeoxycholic Acid × Clear all

NCT04810156 2022-12-14

I-HEP

Herlev Hospital

Phase 2 Unknown

Hepatitis, Neoplasms, Chemical and Drug Induced Liver Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡